GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharming Group (CHIX:PHARMa) » Definitions » Net Interest Income

Pharming Group (CHIX:PHARMA) Net Interest Income : €-9.3 Mil (TTM As of Mar. 2025)


View and export this data going back to 2008. Start your Free Trial

What is Pharming Group Net Interest Income?

Net interest income is the total interest income minus total interest expense. It represents the difference between interest and dividends earned on interestbearing assets and interest paid to depositors and other creditors. Pharming Group's net interest income for the three months ended in Mar. 2025 was €-4.2 Mil. Its net interest income for the trailing twelve months (TTM) ended in Mar. 2025 was €-9.3 Mil.

Pharming Group Net Interest Income Historical Data

The historical data trend for Pharming Group's Net Interest Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharming Group Net Interest Income Chart

Pharming Group Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Net Interest Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only -4.36 -5.43 -5.08 -2.23 -4.86

Pharming Group Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Net Interest Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.21 -1.87 -1.96 -1.30 -4.16

Pharming Group Net Interest Income Calculation

Net interest income is the total interest income minus total interest expense. It represents the difference between interest and dividends earned on interestbearing assets and interest paid to depositors and other creditors.

Net Interest Income for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €-9.3 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pharming Group Net Interest Income Related Terms

Thank you for viewing the detailed overview of Pharming Group's Net Interest Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Pharming Group Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharming Group (CHIX:PHARMa) » Definitions » Net Interest Income
Comparable Companies
XAMS:VVY XAMS:GLPG VRTX ASX:CSL REGN XKRX:207940 ALNY XBRU:ARGX XBRU:UCB ONC XKRX:068270 BNTX SMMT RPRX OCSE:GMAB XKRX:196170 INCY HKSE:02269 INSM HKSE:01801
Traded in Other Exchanges
PHAR:USA PHGUF:USA PHARM:Netherlands 0QCO:UK PHGN:Germany
Address
Darwinweg 24, Leiden, ZH, NLD, 2333 CR
Website
https://www.pharming.com
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.

Pharming Group Headlines

No Headlines